Interaction and cross-resistance of cisplatin and pemetrexed in malignant pleural mesothelioma cell lines

Oncology Reports

Volumn 28, Issue 1, 2012, Pages 33-40

  Kitazono Saitoh, Miyako ^a   Takiguchi, Yuichi ^a   Kitazono, Satoru ^a   Ashinuma, Hironori ^a   Kitamura, Atsushi ^a   Tada, Yuji ^a   Kurosu, Katsushi ^a   Sakaida, Emiko ^a   Sekine, Ikuo ^a   Tanabe, Nobuhiro ^a   Tagawa, Masatoshi ^b   Tatsumi, Koichiro ^a  

^a CHIBA UNIVERSITY   (Japan)

^b CHIBA CANCER CENTER   (Japan)

Author keywords

Cisplatin; Cross resistance; Mesothelioma; Pemetrexed; Synergism

Indexed keywords

CISPLATIN; DIHYDROFOLATE REDUCTASE; MESSENGER RNA; PEMETREXED; PHOSPHORIBOSYLGLYCINAMIDE FORMYLTRANSFERASE; THYMIDYLATE SYNTHASE;

ARTICLE; CANCER CELL; CANCER COMBINATION CHEMOTHERAPY; CELL SURVIVAL; CLONOGENIC ASSAY; CONCENTRATION RESPONSE; CONTROLLED STUDY; CROSS RESISTANCE; DRUG DOSE ESCALATION; DRUG EXPOSURE; DRUG POTENTIATION; DRUG SENSITIVITY; HUMAN; HUMAN CELL; IN VITRO STUDY; MONOTHERAPY; PLEURA MESOTHELIOMA; PRIORITY JOURNAL; PROTEIN EXPRESSION;

ANTINEOPLASTIC AGENTS; CELL LINE, TUMOR; CELL SURVIVAL; CISPLATIN; DRUG INTERACTIONS; DRUG RESISTANCE, NEOPLASM; GLUTAMATES; GUANINE; HUMANS; INHIBITORY CONCENTRATION 50; MESOTHELIOMA; PHOSPHORIBOSYLGLYCINAMIDE FORMYLTRANSFERASE; PLEURAL NEOPLASMS; TETRAHYDROFOLATE DEHYDROGENASE; THYMIDYLATE SYNTHASE;

EID: 84861539787     PISSN: 1021335X     EISSN: 17912431     Source Type: Journal    
DOI: 10.3892/or.2012.1799     Document Type: Article

References (22)

1. Robinson BW and Lake RA: Advances in malignant mesothelioma. N Engl J Med 353: 1591-1603, 2005. (Pubitemid 41434638)
2. O'Brien ME: Malignant mesothelioma - the UK experience. Lung Cancer 45 (Suppl 1): S133-S135, 2004.
3. Niklinski J, Niklinska W, Chyczewska E, et al: The epidemiology of asbestos-related diseases. Lung Cancer 45 (Suppl 1): S7-S15, 2004. (Pubitemid 38917106)
4. Tsao AS, Wistuba I, Roth JA and Kindler HL: Malignant pleural mesothelioma. J Clin Oncol 27: 2081-2090, 2009.
5. Vogelzang NJ, Rusthoven JJ, Symanowski J, et al: Phase III study of pemetrexed in combination with cisplatin versus cisplatin alone in patients with malignant pleural mesothelioma. J Clin Oncol 21: 2636-2644, 2003. (Pubitemid 46606305)
6. Makimoto T, Tsuchiya S, Nakano H, et al: A phase II study of carboplatin-cisplatin-etoposide combination chemotherapy in advanced non-small cell lung cancer. Am J Clin Oncol 20: 51-54, 1997. (Pubitemid 27066478)
7. Shih C, Chen VJ, Gossett LS, et al: LY231514, a pyrrolo[2,3-d]pyrimidine- based antifolate that inhibits multiple folate-requiring enzymes. Cancer Res 57: 1116-1123, 1997. (Pubitemid 27138611)
8. Leichman CG, Lenz HJ, Leichman L, et al: Quantitation of intratumoral thymidylate synthase expression predicts for disseminated colorectal cancer response and resistance to protracted-infusion fluorouracil and weekly leucovorin. J Clin Oncol 15: 3223-3229, 1997. (Pubitemid 27419335)
9. Metzger R, Danenberg K, Leichman CG, et al: High basal level gene expression of thymidine phosphorylase (platelet-derived endothelial cell growth factor) in colorectal tumors is associated with non-response to 5-fluorouracil. Clin Cancer Res 4: 2371-2376, 1998. (Pubitemid 28477901)
10. Salonga D, Danenberg KD, Johnson M, et al: Colorectal tumors responding to 5-fluorouracil have low gene expression levels of dihydropyrimidine dehydrogenase, thymidylate synthase, and thymidine phosphorylase. Clin Cancer Res 6: 1322-1327, 2000. (Pubitemid 30226214)
11. Ichikawa W, Uetake H, Shirota Y, et al: Combination of dihydropyrimidine dehydrogenase and thymidylate synthase gene expressions in primary tumors as predictive parameters for the efficacy of fluoropyrimidine-based chemotherapy for metastatic colorectal cancer. Clin Cancer Res 9: 786-791, 2003. (Pubitemid 36182616)
12. Ishikawa Y, Kubota T, Otani Y, et al: Thymidylate synthetase and dihydropyrimidine dehydrogenase levels in gastric cancer. Anticancer Res 19: 5635-5640, 1999. (Pubitemid 30093342)
13. Huang CL, Yokomise H, Kobayashi S, Fukushima M, Hitomi S and Wada H: Intratumoral expression of thymidylate synthase and dihydropyrimidine dehydrogenase in non-small cell lung cancer patients treated with 5-FU-based chemotherapy. Int J Oncol 17: 47-54, 2000.
14. Gomez HL, Santillana SL, Vallejos CS, et al: A phase II trial of pemetrexed in advanced breast cancer: clinical response and association with molecular target expression. Clin Cancer Res 12: 832-838, 2006. (Pubitemid 43259865)
15. Righi L, Papotti MG, Ceppi P, et al: Thymidylate synthase but not excision repair cross-complementation group 1 tumor expression predicts outcome in patients with malignant pleural mesothelioma treated with pemetrexed-based chemotherapy. J Clin Oncol 28: 1534-1539, 2010.
16. Takezawa K, Okamoto I, Okamoto W, et al: Thymidylate synthase as a determinant of pemetrexed sensitivity in non-small cell lung cancer. Br J Cancer 104: 1594-1601, 2011.
17. Flynn J, Berg RW, Wong T, et al: Therapeutic potential of antisense oligodeoxynucleotides to down-regulate thymidylate synthase in mesothelioma. Mol Cancer Ther 5: 1423-1433, 2006. (Pubitemid 44070478)
18. Kim JH, Lee KW, Jung Y, et al: Cytotoxic effects of pemetrexed in gastric cancer cells. Cancer Sci 96: 365-371, 2005. (Pubitemid 41007472)
19. Kano Y, Akutsu M, Tsunoda S, et al: Schedule-dependent interactions between pemetrexed and cisplatin in human carcinoma cell lines in vitro. Oncol Res 16: 85-95, 2006.
20. Steel GG and Peckham MJ: Exploitable mechanisms in combined radiotherapy-chemotherapy: the concept of additivity. Int J Radiat Oncol Biol Phys 5: 85-91, 1979. (Pubitemid 9120186)
21. Zhang D, Ochi N, Takigawa N, et al: Establishment of pemetrexed- resistant non-small cell lung cancer cell lines. Cancer Lett 309: 228-235, 2011.
22. Giovannetti E, Backus HH, Wouters D, et al: Changes in the status of p53 affect drug sensitivity to thymidylate synthase (TS) inhibitors by altering TS levels. Br J Cancer 96: 769-775, 2007. (Pubitemid 46376640)